Format

Send to

Choose Destination
Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013. Epub 2015 Jul 8.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Author information

1
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: amb107@columbia.edu.
2
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: sulliva@nyspi.columbia.edu.
3
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: glassan@nyspi.columbia.edu.
4
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: mishlen@nyspi.columbia.edu.
5
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: mp2370@columbia.edu.
6
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: haneyme@nyspi.columbia.edu.
7
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: rabywil@nyspi.columbia.edu.
8
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: levinfr@nyspi.columbia.edu.
9
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: carpent@nyspi.columbia.edu.
10
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: mariani@nyspi.columbia.edu.
11
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. Electronic address: nunesed@nyspi.columbia.edu.

Abstract

BACKGROUND:

Evidence suggests that the cannabinoid system is involved in the maintenance of opioid dependence. We examined whether dronabinol, a cannabinoid receptor type 1 partial agonist, reduces opioid withdrawal and increases retention in treatment with extended release naltrexone (XR-naltrexone).

METHODS:

Opioid dependent participants were randomized to receive dronabinol 30mg/d (n=40) or placebo (n=20), under double-blind conditions, while they underwent inpatient detoxification and naltrexone induction. Before discharge all participants received an injection of XR-naltrexone, with an additional dose given four weeks later. Dronabinol or placebo was given while inpatient and for 5 weeks afterwards. The primary outcomes were the severity of opioid withdrawal, measured with the Subjective Opioid Withdrawal Scale, and retention in treatment at the end of the inpatient phase and at the end of the 8-week trial.

RESULTS:

The severity of opioid withdrawal during inpatient phase was lower in the dronabinol group relative to placebo group (p=0.006). Rates of successful induction onto XR-naltrexone (dronabinol 66%, placebo 55%) and completion of treatment (dronabinol 35%, placebo 35%) were not significantly different. Post hoc analysis showed that the 32% of participants who smoked marijuana regularly during the outpatient phase had significantly lower ratings of insomnia and anxiety and were more likely to complete the 8-week trial.

CONCLUSION:

Dronabinol reduced the severity of opiate withdrawal during acute detoxification but had no effect on rates of XR-naltrexone treatment induction and retention. Participants who elected to smoke marijuana during the trial were more likely to complete treatment regardless of treatment group assignment.

KEYWORDS:

Cannabinoid; Dronabinol; Naltrexone; Opiate dependence; Pharmacotherapy trials; Randomized Trial; Treatment

PMID:
26187456
PMCID:
PMC4536087
DOI:
10.1016/j.drugalcdep.2015.05.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center